VivoSim Labs announced regained compliance with Nasdaq Listing Rule 5550(b)(1) regarding minimum stockholders' equity of $2.5 million following a $5.0 million milestone payment from Eli Lilly and a $4.0 million financing transaction in July 2026. The company reported preliminary cash on hand of approximately $10.1 million as of August 3, 2026, with common shares outstanding increasing to 13,390,789 due to warrant exercises. Management anticipates over 500% revenue growth in fiscal year 2027 driven by its contract research services using new approach methodologies (NAMs). VivoSim Labs operates as a pharmaceutical and biotechnology services company focused on providing preclinical safety testing of drug candidates using three-dimensional human tissue models.
